4-苯基-5-(三氟甲基)-2-噻吩羧酸酰氯 | 208108-75-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4-苯基-5-(三氟甲基)-2-噻吩羧酸酰氯
• 英文名称: 5-trifluoromethyl-4-phenyl-thiophene-2-carboxylic acid chloride
• 英文别名: 4-phenyl-5-(trifluoromethyl)thiophene-2-carbonyl chloride
• CAS: 208108-75-2
• 化学式: C₁₂H₆ClF₃OS
• 分子量: 290.693
• InChiKey: MSBBSNNRGFMNHU-UHFFFAOYSA-N

物化性质

• 熔点：
  48 °C
• 沸点：
  161/0.5mm
• 密度：
  1.424±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-苯基-5-(三氟甲基)-2-噻吩羧酸酰氯 在 吡啶 、 四丙基高钌酸铵 、 4 A molecular sieve 、 二异丁基氢化铝 、 N-甲基吗啉氧化物 作用下， 以 二氯甲烷 、 乙腈 、 xylene 为溶剂， 反应 4.0h， 生成 3-[(4-甲酰基)苯基]-5-(4-苯基-5-三氟甲基-2-噻吩基)-1,2,4-恶二唑
  参考文献：
  名称：

  A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists

  摘要：

  Moderately potent, selective SIP, receptor agonists identified from high-throughput screening have been adapted into lipophilic tails for a class of orally bioavailable amino acid-based S1P(1) agonists represented by 7. Many of the new compounds are potent S1P(1) agonists that select against the S1P(2), S1P(3), and S1P(4) (although not S1P(5)) receptor subtypes. Analogues 18 and 24 are highly orally bioavailable and possess excellent pharmacokinetic profiles in the rat, dog, and rhesus monkey.

  DOI：

  10.1021/jm0492507
• 作为产物：
  描述：

  1,1,1-三氟-3-苯基丙酮 在 sodium hydroxide 、 草酰氯 、 sodium hydride 、 N,N-二甲基甲酰胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 41.5h， 生成 4-苯基-5-(三氟甲基)-2-噻吩羧酸酰氯
  参考文献：
  名称：

  A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists

  摘要：

  Moderately potent, selective SIP, receptor agonists identified from high-throughput screening have been adapted into lipophilic tails for a class of orally bioavailable amino acid-based S1P(1) agonists represented by 7. Many of the new compounds are potent S1P(1) agonists that select against the S1P(2), S1P(3), and S1P(4) (although not S1P(5)) receptor subtypes. Analogues 18 and 24 are highly orally bioavailable and possess excellent pharmacokinetic profiles in the rat, dog, and rhesus monkey.

  DOI：

  10.1021/jm0492507

文献信息

• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS SPHINGOSINE-1-PHOSPHATE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011017578A1

  公开（公告）日：2011-02-10

  Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物，或其立体异构体或药用可接受的盐，其中：A为Formula (II)，Q为取代的5-成员单环杂芳基团；W为CH2、O或NH；而R1、R2、R3、R4、R5、R6、m、n、t和x在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 AGONIST AND LIPOSOMAL FORMULATIONS THEREOF<br/>[FR] AGONISTE DU RÉCEPTEUR 1 DE LA SPHINGOSINE-1-PHOSPHATE ET FORMULATIONS LIPOSOMALES ASSOCIÉES
  申请人：PENN STATE RES FOUND

  公开号：WO2021262311A1

  公开（公告）日：2021-12-30

  The present disclosure is directed to a compound or compositions comprising the same for decreasing vascular permeability and the prevention or inhibition of metastasis in a cancer.

  本公开涉及一种化合物或包含该化合物的组合物，用于降低血管通透性并预防或抑制癌症的转移。
• Microbicidal agents based on thiophene-2-carboxylic acid derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US06013664A1

  公开（公告）日：2000-01-11

  Novel microbicidal compositions based on thiophene-2-carboxylic acid derivatives, some of which are known, of the formula in which R.sup.1, R.sup.2 and n have the meanings given in the description, and the use of these substances for controlling undesired microorganisms. Novel thiophene-2-carboxylic acid derivatives of the formula ##STR1## in which R.sup.1, R.sup.2 and p have the meanings given in the description, and a process for the preparation of the substances of the formula (I-a).

  基于噻吩-2-羧酸衍生物的新型杀菌组合物，其中一些是已知的，其化学式中R.sup.1，R.sup.2和n的含义如描述中所示，并且利用这些物质来控制不良微生物。化学式为##STR1##其中R.sup.1，R.sup.2和p的含义如描述中所示的新型噻吩-2-羧酸衍生物，以及制备式（I-a）物质的方法。
• Novel therapeutic compounds
  申请人：Breinlinger Eric C.

  公开号：US20090069288A1

  公开（公告）日：2009-03-12

  Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.

  本文公开了公式（I）的新化合物，其中变量如本文所定义。公式（I）的化合物可用作激酶抑制剂，因此可用于治疗某些疾病和病症，特别是炎症性疾病和疾病以及增生性疾病，如癌症。
• Heterocyclic compound
  申请人：Nishi Takahide

  公开号：US20080113961A1

  公开（公告）日：2008-05-15

  A compound having immunosuppressive activity with low toxicity or a pharmacological salt thereof. The compound has a general formula (I) shown below or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable prodrug thereof

  具有低毒性免疫抑制活性的化合物或其药理盐。该化合物具有下面所示的一般式（I）或其药理学上可接受的盐，或其药理学上可接受的前体。